Has anyone tried Piribedil
It is a D2/D3 Agonist and alpha 2 präsyn.antagonist(the same as vor example yohimbe)
Posted 11 October 2006 - 06:10 PM
Posted 11 October 2006 - 07:14 PM
Posted 11 October 2006 - 07:31 PM
Has anyone tried Piribedil
It is a D2/D3 Agonist and alpha 2 präsyn.antagonist(the same as vor example yohimbe)
Fundam Clin Pharmacol. 2002 Feb;16(1):57-65.Click here to read
Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers.
* Schuck S,
* Bentue-Ferrer D,
* Kleinermans D,
* Reymann JM,
* Polard E,
* Gandon JM,
* Allain H.
Laboratoire de Pharmacologie Experimentale et Clinique, Universite de Rennes I - Faculte de Medecine, CS 34317, 35 043 Rennes cedex, France.
Piribedil is a dopamine agonist acting on D2 and D3 central nervous system dopamine receptors. This drug has been administered to 12 young healthy male volunteers (age 22 +/- 2 years) according to a single center randomized, double-blind, two ways cross-over, placebo controlled trial, including a washout period of one week. Placebo and piribedil were administered by a single intravenous infusion over 2 h (3 mg). Psychomotor performance and cognitive functions were assessed through a standardized and computerized psychometric tests battery and a continuous electroencephalogram (EEG) mapping. Piribedil improved simple reaction time (P=0.02), immediate (P=0.045 and 0.004), and delayed free recall (P=0.05), dual coding test (P=0.02) and increased theta and fast beta waves on the EEG (P < 0.05 and 0.001, respectively). No deleterious effect was observed on the tests exploring attention and concentration via the other procedures. It is concluded that a single intravenous perfusion of piribedil 3 mg improves alertness and the information processing speed within the central nervous system, in healthy volunteers.
PMID: 11903513 [PubMed - indexed for MEDLINE]
Psychopharmacology (Berl). 2004 Nov;176(2):175-81. Epub 2004 May 12.
Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil.
* Peretti CS,
* Gierski F,
* Harrois S.
Service de Psychiatrie des Adultes, Hopital Robert Debre, CHU de Reims, Avenue du General Koenig, 51092, Reims Cedex, France. cperetti@chu-reims.fr
RATIONALE: Cognitive skill learning, as assessed by repeated testing on the Tower of Toronto (TT) task, has been found to be impaired in normal aging. There is evidence that this impairment might be accounted for by the well-documented, age-dependent decline of dopamine D2-like receptor availability. OBJECTIVES: This study was an investigation of whether the D2/D3 dopaminergic agonist piribedil improves cognitive skill learning in older adults. METHODS: Healthy elderly volunteers were assessed using the TT paradigm. Subjects were evaluated at baseline, and after 2 months of a placebo or piribedil (50 mg daily) treatment in a double-blind, crossover design. Two components of cognitive skill learning were considered--the ability to learn to solve the puzzle and the acquisition of a problem-solving routine. RESULTS: Piribedil showed a beneficial effect on the acquisition of a problem-solving routine, depending on the age of subjects, as revealed by solution reliability indexes measures. The effect of piribedil on the ability to learn to solve the puzzle was found to be dependent on the subject's working memory capacities. CONCLUSIONS: The present results suggest that piribedil is likely to enhance cognitive skill learning in healthy older adults and give further evidence that age-related dopamine decline plays an important role in cognitive impairment occurring in normal aging.
PMID: 15138753 [PubMed - indexed for MEDLINE]
Side effects of Dopamine Agonists
Dopamine agonists can cause nausea, vomiting, and orthostatic hypotension by stimulating peripheral dopamine receptors. They may also cause central dopaminergic side effects such as nightmares, hallucinations, or psychiatric symptoms. Cognitive side effects are dose related but nausea and orthostatic hypotension can occur even with small initial doses. Other possible side effects include leg edema and constipation.
Posted 11 October 2006 - 09:26 PM
Posted 11 October 2006 - 09:40 PM
Posted 11 October 2006 - 09:50 PM
Posted 13 October 2006 - 12:08 PM
Posted 16 April 2009 - 11:46 PM
Posted 17 April 2009 - 02:52 AM
Posted 04 September 2018 - 05:00 AM
It's absolutely insane how much reports on this one vary - either people love it or they hate it, as seen in this thread. It's a partial dopamine agonist, so it's quite a bit safer than a full dopamine agonists. I'm very much considering trying it given how promising some of the reports seem to be.
Anyone have any new updates to share about this stuff? Any information would be highly appreciated
Edited by jacobjerondin, 04 September 2018 - 05:00 AM.
0 members, 2 guests, 0 anonymous users